CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 104 enrolled
Drug / intervention
Rifaximin 550 milligram Oral Tablet [XIFAXAN]drug
Likely dose
Rifaximin 550 milligram Oral Tablet [XIFAXAN]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05621005
NCT05621005Phase 2Completed
CompareCT.gov

Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients

Samar Atef Sebaweh Mohammed·interventional·Posted Nov 17, 2022·Updated Nov 21, 2022

In Brief

A Phase 2 clinical trial evaluating Rifaximin 550 milligram Oral Tablet [XIFAXAN] for Ascites Infection. Completed, enrolled 104 participants across 1 site.

Detailed Summary

Norfloxacin is the most commonly used drug for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. Rifaximin, another broad spectrum antibiotic with only trivial absorption from the gut, is used for the treatment of traveler's diarrhea and prevention of hepatic encephalopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAscites Infection
CountriesEgypt
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 17, 2022
Enrollment StartMar 1, 2019
Primary CompletionJul 1, 2022
Study CompletionAug 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 3.6 years ago

Interventions

Rifaximin 550 milligram Oral Tablet [XIFAXAN]drug

Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months